$Atea Pharmaceuticals (AVIR.US)$
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
Monday, 16th December at 5:00 am
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has engaged Evercore, a global independent investment bank, to identify potentia...

$Atea Pharmaceuticals (AVIR.US)$ good news why drop??  surprise

$Atea Pharmaceuticals (AVIR.US)$ uhh hello 99% success rate

$Atea Pharmaceuticals (AVIR.US)$
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Atea Pharmaceuticals (AVIR) presented three posters at AASLD's The Liver Meeting 2024 supporting the combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) treatment.
The Phase 2 lead-in cohort showed a 97% SVR12 success rate with an 8-week treatment course.
Key f...

$Atea Pharmaceuticals (AVIR.US)$
NEWS
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

$Atea Pharmaceuticals (AVIR.US)$
NEWS
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
Atea Pharmaceuticals, Inc. announced the Phase 1 data presentation at ESCMID Global 2024, highlighting the favorable safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor. The results show no cardiotoxicity in healthy participants, supporting the drug's safety profile. Atea aims to address the unmet need for COVID-19 and HCV trea...

$Atea Pharmaceuticals (AVIR.US)$  😎

$Pfizer (PFE.US)$  Phase 3
$BioCardia (BCDA.US)$  Phase 3
$Atea Pharmaceuticals (AVIR.US)$  Phase 3
$Crinetics (CRNX.US)$  Phase 3
$Axsome Therapeutics (AXSM.US)$  Phase 3
$ROCHE HOLDING AG (RHHBY.US)$  Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$  Phase 3
$Sellas Life Sciences (SLS.US)$  Phase 3
$Aquestive Therapeutics (AQST.US)$  Phase 3
$Jaguar Health (JAGX.US)$  Phase 3
$Novocure (NVCR.US)$  Phase 3
$Johnson & Johnson (JNJ.US)$  Phase 3

🎯 Ph 3 readouts in Q1 2024...
$Pfizer (PFE.US)$  Phase 3
$Palatin Technologies (PTN.US)$  Phase 3
$Annovis Bio (ANVS.US)$  Phase 3
$BioCardia (BCDA.US)$  Phase 3
$Atea Pharmaceuticals (AVIR.US)$  Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$  Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$  Phase 3
$Axsome Therapeutics (AXSM.US)$  Phase 3
$ $Novocure (NVCR.US)$  Phase 3
$ROCHE HOLDING AG (RHHBY.US)$  Phase 3
$FibroGen (FGEN.US)$  Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$  Phase 3
$Sellas Life Sciences (SLS.US)$...

$Atea Pharmaceuticals (AVIR.US)$  good looking chart 😎😎. Drop us some news !